Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

BioMarin Pharmaceutical Inc. (BMRN) had Revenue of $766.21M for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$766.21M
Net Income	$105.53M
Cost of Goods Sold	$195.00M
Gross Profit	$571.21M
Operating Expenses	$636.57M
Operating Income	$129.64M
Non-Operating Income/Expense	$11.56M
Pre-Tax Income	$141.20M
Normalized Pre-Tax Income	$141.20M
Income after Taxes	$105.53M
Income from Continuous Operations	$105.53M
Consolidated Net Income/Loss	$105.53M
Normalized Income after Taxes	$105.53M
EBIT	$129.64M
EBITDA	$145.60M
Weighted-Average Shares Outstanding (Basic)	192.50M
Weighted-Average Shares Outstanding (Diluted)	197.67M
Earnings per Share (EPS) (Basic)	$0.55
Earnings per Share (EPS) (Diluted)	$0.54
Balance Sheet Financials
Current Assets	$4.61B
Property, Plant, and Equipment	$958.07M
Long-Term Assets	$3.99B
Total Assets	$8.59B
Current Liabilities	$793.15M
Long-Term Debt	$1.43B
Long-Term Liabilities	$1.59B
Total Liabilities	$2.38B
Common Equity	$6.21B
Tangible Shareholders Equity	$5.81B
Shareholders Equity	$6.21B
Common Shares Outstanding	193.27M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$220.65M
Cash Flow from Investing Activities	$725.53M
Cash Flow from Financial Activities	$813.17M
Beginning Cash	$1.31B
End Cash	$3.07B
Increase/Decrease in Cash	$1.76B
Stock-Based Compensation	$43.46M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.81
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.19
Debt to Equity Ratio	0.23
Gross Margin	74.55%
Operating Margin	16.92%
EBIT Margin	16.92%
EBITDA Margin	--
Pre-Tax Profit Margin	18.43%
Profit Margin	13.77%
Free Cash Flow	$199.73M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.09
Inventory Turnover	0.15
Receiveable Turnover	0.85
Days Sales in Receivables	106.18
Return on Equity	1.70%
Return on Tangible Equity	1.82%
Return on Assets	1.23%
Return on Investments	1.38%
Book Value Per Share	$32.14
Free Cash Flow per Share	$1.01
Operating Cash Flow per Share	$1.12

Data from Zacks Investment Research, Inc.